Article
Chemistry, Multidisciplinary
Da-cai Xu, Li Yang, Pei-quan Zhang, Ding Yan, Qian Xue, Qing-tian Huang, Xiao-fen Li, Ya-li Hao, Dao-lin Tang, Q. Ping Dou, Xin Chen, Jin-bao Liu
Summary: The study synthesized a novel gold (I) complex named Na-AuPT that exhibited high water solubility and potent inhibitory effects on the growth of multiple cancer cell lines, as well as induction of apoptosis. In nude mice bearing xenografts, Na-AuPT administration significantly inhibited tumor growth and induced cell death of primary mononuclear cells from patients with acute myeloid leukemia, suggesting its potential as a promising metal-based proteasome inhibitor for cancer therapy.
ACTA PHARMACOLOGICA SINICA
(2022)
Article
Oncology
Tian-Yi Jiang, Xiao-Fan Feng, Zheng Fang, Xiao-Wen Cui, Yun-Kai Lin, Yu-Fei Pan, Chun Yang, Zhi-Wen Ding, Yong-Jie Zhang, Ye-Xiong Tan, Hong-Yang Wang, Li-Wei Dong
Summary: This study identified frequent alterations of PTEN in GBC, showing correlation with poor prognosis, and indicated proteasome inhibitor bortezomib as a promising therapeutic agent. Knockdown of PTEN increased bortezomib efficacy, and further evaluation using PDXs supported the utilization of bortezomib in PTEN-deficient GBC. Mechanistically, PTEN inhibited proteasome activity and bortezomib sensitivity through ARE-dependent transcriptional regulation, with involvement of the BACH1 transcriptional suppressor.
Article
Oncology
Kayhan Mehdizadeh, Farangis Ataei, Saman Hosseinkhani
Summary: The combination of proteasome inhibitor and Docetaxel shows enhanced cytotoxic effects on MCF7 breast cancer cells, delaying cell growth, and increasing ROS production. Cells overexpressing Apaf-1 are more susceptible to Docetaxel, but the addition of proteasome inhibitor does not significantly improve the response.
Article
Biochemistry & Molecular Biology
Harriet Ghansah, Ildiko Beke Debreceni, Zsolt Fejes, Bela Nagy, Janos Kappelmayer
Summary: The study revealed that Bortezomib (BTZ) induces a procoagulant platelet phenotype, leading to increased phosphatidylserine (PS) and P-selectin expression levels, as well as depolarization of mitochondrial inner membrane potential in gel-filtered platelets (GFPs) compared to platelet-rich plasma (PRP). The presence of plasma proteins in PRP may attenuate the procoagulant effect of BTZ on platelets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Kyota Ishii, Mayuko Hido, Misaki Sakamura, Nantiga Virgona, Tomohiro Yano
Summary: This study demonstrated that T3, TOS, and T3E enhance the sensitivity of the proteasome inhibitor BTZ in solid cancers by modulating the activity of NFE2L1. Inactivation of NFE2L1 by T3, TOS, and T3E is essential to potentiate the cytotoxic effect of BTZ in solid cancers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Mingyu Chen, Sarun Juengpanich, Shijie Li, Win Topatana, Ziyi Lu, Qiang Zheng, Jiasheng Cao, Jiahao Hu, Esther Chan, Lidan Hou, Jiang Chen, Fang Chen, Yu Liu, Sukanda Jiansirisomboon, Zhen Gu, Suparat Tongpeng, Xiujun Cai
Summary: This study reports on a targeted therapy for gallbladder cancer using pH-responsive nanoparticles encapsulating bortezomib and mediated by estrogen-induced endocytosis. The treatment effectively inhibits proteasomes and induces apoptosis under tumor microenvironment and laser irradiation.
Article
Cell Biology
Emir Bozkurt, Heiko Dussmann, Manuela Salvucci, Brenton L. Cavanagh, Sandra Van Schaeybroeck, Daniel B. Longley, Seamus J. Martin, Jochen H. M. Prehn
Summary: The study reveals that TRAIL signaling not only activates apoptosis in colon cancer cells but also induces entosis through TRAIL receptors and the structural presence of caspase-8. The association of TRAIL signaling with cell-in-cell structures is significant in colorectal cancer, especially in the context of patient prognosis. Factors controlling entosis in tumors remain to be elucidated despite the evidence of entosis in cancers.
JOURNAL OF CELL BIOLOGY
(2021)
Article
Chemistry, Inorganic & Nuclear
Adriana Celesia, Tiziana Fiore, Diana Di Liberto, Michela Giuliano, Claudia Pellerito, Sonia Emanuele
Summary: Organotin(IV) complexes are potential drugs for cancer therapy. We have reported a new organotin(IV) complex, tributyltin(IV) ferulate (TBT-F), which exhibits antitumor activity in colon cancer cells. In this study, we show that the effectiveness of TBT-F is greatly enhanced when combined with the proteasome inhibitor bortezomib (BTZ). The combination of the two compounds leads to a significant reduction in colon cancer cell viability, disruption of cell morphology, and exacerbation of endoplasmic reticulum stress. This stress promotes apoptosis through the unfolded protein response pathway.
INORGANICA CHIMICA ACTA
(2022)
Article
Multidisciplinary Sciences
Mengmeng Dong, Jinna Zhang, Xiaoyan Han, Jingsong He, Gaofeng Zheng, Zhen Cai
Summary: This study retrospectively analyzed clinical data of 155 MM patients and found that baseline PN was age-related, leading to more severe BiPN during bortezomib induction therapy and worse PN outcome after induction therapy. MM patients with baseline PN also had worse PFS and OS.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Xueqiong Meng, Xiaoxi Cui, Xiaoya Shao, Yanqi Liu, Yihao Xing, Victoria Smith, Shiqiu Xiong, Salvador Macip, Yixiang Chen
Summary: The combination of dsRNA poly(I:C) and proteasome inhibitors synergistically induce apoptosis in cervical cancer cells by activating multiple pro-apoptotic pathways, suggesting a potential therapeutic combination.
TRANSLATIONAL ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Anderson Luiz-Ferreira, Teresa Pacifico, Alefe Cardoso Cruz, Federica Laudisi, Giovanni Monteleone, Carmine Stolfi
Summary: TRAIL is a promising anticancer agent that selectively induces apoptosis in transformed cells, while flavonoids, natural compounds found in plants, have shown competence in enhancing TRAIL-induced apoptosis. However, bioavailability issues are the main limitations for the clinical use of flavonoids.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Gregoire Quinet, Wendy Xolalpa, Diana Reyes-Garau, Nuria Profitos-Peleja, Mikel Azkargorta, Laurie Ceccato, Maria Gonzalez-Santamarta, Maria Marsal, Jordi Andilla, Fabienne Aillet, Francesc Bosch, Felix Elortza, Pablo Loza-Alvarez, Brigitte Sola, Olivier Coux, Rune Matthiesen, Gael Roue, Manuel S. Rodriguez
Summary: The research identified an enrichment of autophagy-lysosome system (ALS) components in bortezomib (BTZ)-resistant cells in mantle cell lymphoma (MCL) patients. By blocking proteaphagy, the normal proteasomal activity was reactivated and the BTZ antitumor effect was restored in vitro and in vivo models of BTZ resistance. These findings suggest a proteolytic switch from the ubiquitin-proteasome system (UPS) to ALS in B-cell lymphoma refractory to proteasome inhibition, opening up new therapeutic avenues for treatment-resistant tumors.
Article
Biology
Min Seung Lee, So Hyun Lim, Ah-Ran Yu, Chi Yeon Hwang, Insug Kang, Eui-Ju Yeo
Summary: The study showed that proteasome inhibitors bortezomib and carfilzomib induce apoptosis and endoplasmic reticulum stress in melanoma cells, leading to potential therapeutic effects against melanoma. Combination therapy of carfilzomib and bortezomib at submaximal concentrations synergistically reduced tumor growth, suggesting a promising strategy for the treatment of melanoma.
Review
Oncology
Ramon Yarza, Mateo Bover, Maria Teresa Agullo-Ortuno, Lara Carmen Iglesias-Docampo
Summary: Nasopharyngeal carcinoma (NPC) is a molecularly paradigmatic tumor with complex environmental and host dependent factors, where Epstein Barr Virus (EBV) plays a key role in malignant transformation. The dysregulation of proteasome signaling is central in NPC pathogenesis and could be a potential therapeutic target. Studies have shown the efficacy of immunotherapy in NPC, with novel strategies aiming to reverse immune resistance and favor tumor recognition.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
You-Take Oh, Shi-Yong Sun
Summary: The involvement of the TRAIL/death receptor signaling pathway in the regulation of cancer invasion and metastasis is complex, with both positive and negative roles reported. The underlying molecular mechanisms are even more complicated. This review focuses on discussing the current understanding of how TRAIL/death receptor-mediated signaling regulates cancer cell invasion and metastasis.